Walgreens expands preventive healthcare services to Maryland market
DEERFIELD, Ill. — Further expanding the scope of preventive healthcare services provided by its pharmacists, Walgreens as of Monday is now offering daily testing for cholesterol, blood glucose and body composition at more than 60 stores in Maryland.
Each test also includes a free blood pressure reading and personal consultation with a Walgreens pharmacist.
“Providing convenient, affordable access to health testing services is an important part of our commitment to disease prevention and chronic care management,” stated Jon Reitz, market pharmacy director, Walgreens. “As the most accessible health care providers, our pharmacists are spending more time with patients through consultations, immunizations, medication questions or concerns, health testing and other important services to help our customers get, stay and live well.”
Tests are available to those ages 18 and over at most stores during pharmacy hours daily with no appointment necessary.
Walgreens offers health testing daily at more than 4,100 stores in 41 states.
Walgreens pharmacists administer tests by fingerstick. Cost for testing is:
- Total Cholesterol – $35;
- Blood Glucose – $20;
- Body Composition – $15;
- Wellness Pack: Cholesterol, Blood Glucose and Body Composition – $65; and
- Blood pressure – free with every health test.
Test results are not for diagnostic or treatment purposes and are not conclusive as to the absence or presence of any health condition. Customers are encouraged to share test results with their primary care physician.
The National Heart, Lung and Blood Institute recommends that all adults have their cholesterol levels checked at least every five years. However, adults over age 45 or with other risk factors for heart disease or stroke should talk with their primary care physician about whether more frequent testing is necessary. Walgreens total cholesterol tests include a review of triglycerides, HDL and LDL.
According to the U.S. Centers for Disease Control and Prevention, one-third of U.S. adults have high cholesterol, which can significantly increase the risk of heart disease or stroke.
The American Diabetes Association recommends blood glucose testing every three years for people with normal levels or in good health with no risk factors. Those who are overweight and/or over age 45 should talk with their doctor about whether more frequent testing is recommended.
The American Heart Association recommends body composition tests to detect various health problems including high blood pressure and diabetes which can increase risk for heart disease and stroke.
APhA Foundation appoints five new board members
WASHINGTON — The American Pharmacists Association’s philanthropic wing has appointed five new members to its board of directors, the group said Monday.
The APhA Foundation announced in September the official installment of Stuart Haines, professor of and vice chairman for clinical services in the Unviersity of Maryland School of Pharmacy’s Department of Pharmacy Practice and Science in Baltimore, as well as a clinical pharmacy specialist in primary care at the West Palm Beach, Fla., VA Medical Center.
The other members will be installed during the APhA2014 Annual Meeting in Orlando, Fla., in March. They are Timothy Canning, who has worked in the healthcare field in positions ranging from operations to marketing, primarily related to retail pharmacy, including positions at McKesson and Health Mart; Jerry Moore is the director of state government affairs for Teva Pharmaceuticals; Megan Tucker is SVP at Edelman’s Healthcare Practice in Washington; and commander Kelly Valente became a regional pharmacist for the Centers for Medicare and Medicaid Services in Boston this year, with previous experience working in the Federal Bureau of Prisons.
Plan to reorganize FDA’s Office of Generic Drugs receives approval
WASHINGTON — The Food and Drug Administration’s Office of Generic Drugs will be elevated to a "super office," a top official in the agency told staff members in a memo Monday.
Janet Woodcock, the director of the FDA’s Center for Drug Evaluation and Research, of which the OGD is a part, said the elevation of the office meant it would house subordinate offices within its organizational structure and would report directly to her, with acting director Kathleen Uhl continuing in that role. Woodcock said the reorganization, plans for which were originally announced in September 2012, would strengthen the OGD’s operations and allow it to "meet the evolving needs of generic drug review."
"Transforming OGD into a super office is a critical and necessary step in recognizing the importance of generic drugs to public health and our national economy," Woodcock wrote. "As a super office, OGD will coordinate and manage the abbreviated new drug application review process, provide safety, surveillance, clinical and bioequivalence reviews for generic products, as well as contain new offices to develop policy and regulatory science for generic drugs."
The new structure of the OGD will include an Office of Research and Standards, an Office of Bioequivalence, an Office of Generic Drug Policy and an Office of Regulatory Operations, each of which will have multiple divisions under it. Members of a transition team will lead the offices.